Lung cancer: AI shows who will benefit from immunotherapy

Lung cancer is a common and often aggressive form of cancer. As it is difficult for doctors to detect it early on, people with lung cancer need to receive the best, most targeted therapy in order to make a positive outlook more likely. Immunotherapy is an option, but how can doctors know who will benefit? According to the National Cancer Institute, lung and bronchus cancer is the second most widespread type of cancer among people in the United States, accounting for 12.9% of all new cancer cases. This form of cancer often has no noticeable symptoms in its early stages, which can mean that doctors are unable to detect it at first.